Navigation Links
NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy
Date:12/4/2009

BOSTON and HOUSTON, Dec. 4 /PRNewswire-FirstCall/ -- AES Annual Meeting, Booth #901-- Cyberonics, Inc. (Nasdaq: CYBX) announced today that Vagus Nerve Stimulation (VNS) Therapy, the only FDA-approved implantable medical device for the treatment of refractory epilepsy, will be featured in 14 presentations at the American Epilepsy Society's (AES) Annual Meeting, taking place December 4-8 at the Hynes Convention Center in Boston, Massachusetts.

Robert Elliott, M.D., chief resident of Neurosurgery at NYU Langone Medical Center, will present results of the study entitled, "Vagus Nerve Stimulation for Refractory Epilepsy: Single Surgeon Experience of over 700 Consecutive Operations," on Monday, December 7 at 4:00 p.m. The study was designed to analyze the efficacy and safety of VNS Therapy in a large series of consecutive adults and children with medically refractory epilepsy.

Dr. Elliott and his colleagues at NYU Langone Medical Center conducted a retrospective review of 507 consecutive patients with refractory epilepsy who underwent a total of 720 VNS-related procedures between November 1997 and April 2008. Outcome analysis was performed on 436 patients who underwent primary implantation at the center and had at least one year of follow-up since implantation. Duration of VNS Therapy ranged from one week to 11.35 years.

The results showed a more than 50 percent reduction in seizure frequency occurred in 64.6 percent of patients and 42.1 percent of patients experienced more than a 70 percent reduction in seizure frequency. Patients who had failed intracranial epilepsy procedures prior to VNS Therapy had similar outcomes to those who did not have prior surgery. There were no significant differences in efficacy between adults and children.

"Our study reviewing more than 700 consecutive VNS Therapy procedures further confirms the safety and efficacy of VNS Therapy for medically refractory epilepsy," said Dr. Elliot. "Patients evaluated in this study varied in age, seizure frequency and treatment histories, and the vast majority of patients saw significant improvements in their seizure control. VNS Therapy continues to be an effective way to treat medically refractory epilepsy while possibly improving the quality-of-life for patients."

"Dr. Elliott's study reaffirms the safety, efficacy and quality-of-life benefits of VNS Therapy," said Dan Moore, president and CEO of Cyberonics. "Worldwide, more than 50,000 patients with epilepsy have received VNS Therapy, and a significant majority of these patients are consistently opting to continue treatment, which is evidenced by an initial reimplant rate that exceeds 70 percent. These findings further establish VNS Therapy as the best option for patients with medically refractory epilepsy who are not candidates for resective surgery or who have failed resective surgery."

About Cyberonics, Inc. and VNS Therapy(® )

Cyberonics, Inc. (Nasdaq: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy is available at http://www.cyberonics.com and www.vnstherapy.com.


Contact:
Helen Shik or Amanda Lazaro Connolly
Schwartz Communications
781-684-0770
cyberonicsepilepsy@schwartz-pr.com

SOURCE Cyberonics, Inc.


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kenneth G. Langone, Home Depot Co-Founder, Chairman of the NYU Langone Medical Center, to Lead 65th Annual Columbus Day Parade as Grand Marshal
2. NYU Langone Medical Centers tip sheet to the 45th Annual Meeting of ASCO
3. NYU Langone Medical Center study shows that cochlear implant surgery is safe for the elderly
4. SIRIUS Satellite Radio & NYU Langone Medical Center Launch Doctor Radio Channel
5. NYU Langone Medical Centers tip sheet to the 44th annual meeting of ASCO
6. North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program
7. IntelliSoft Group Focuses on Protecting Customer Investment in Medical Credentialing Systems -- Budget Constraints and Forced Upgrades in Medical Credentialing Automation
8. Florida Medical Association Marks Record Membership Growth
9. Topping Out Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro
10. Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs
11. Personality predicts success in medical school, says new study by U of Minnesota professor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Irvine, CA — , ... ... the appointment of three new members of its Advisory Board. ... Chico and Sarah Kusch. “All three of them embody the mission ... team. We are very fortunate to have them as we continue ...
(Date:5/24/2016)... ... May 24, 2016 , ... Boyd Industries, a leading supplier of ... a groundbreaking new product for pediatric dentistry , at AAPD 2016, the annual ... TX May 26-29. The Concealed Delivery Unit keeps dental hand pieces and other anxiety-provoking ...
(Date:5/24/2016)... ... May 24, 2016 , ... Eggsurance, the first ... relaunch of its community and education hub for women considering fertility preservation, as ... create a safe and welcoming place for women to find cycle buddies, get ...
(Date:5/24/2016)... ... May 24, 2016 , ... American Gene Technologies ... to its board of directors. Otterstatter is co-founder, president and CEO of ... technological innovations that lead to broad-based healthcare solutions. , “Jon knows how to ...
(Date:5/24/2016)... ... May 24, 2016 , ... Bio-Logic Aqua® Research Water Life ... and a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss healthier lifestyles, ... 16, 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated to her ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... 2016 ReportsnReports.com adds Global ... Devices of its online business intelligence library. This ... current state of the Titrator industry. The report ... definitions, classifications, Specifications, applications and industry chain structure. ... Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost Structure, ...
(Date:5/20/2016)... 20, 2016 - Revenue ... Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative ... This New Study Reveals Selling Opportunities and Revenue ... ,What is the future of biologics, especially ... and commercial analysis. Staying ahead in data and ...
(Date:5/20/2016)... , May 20, 2016 ... Review, H1 2016" market research report with comprehensive ... (Psoriasis Vulgaris), complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ...
Breaking Medicine Technology: